Figure 3.
Outcomes in recipients of KIR3DL1-Weak Inhibiting compared with KIR3DL1-Strong Inhibiting or KIR3DL1- Noninteracting donor recipients in patients with AML. OS (A), cumulative incidence of relapse (B), cumulative incidence of NRM (C), and cumulative incidence of acute GVHD (D).

Outcomes in recipients of KIR3DL1-Weak Inhibiting compared with KIR3DL1-Strong Inhibiting or KIR3DL1- Noninteracting donor recipients in patients with AML. OS (A), cumulative incidence of relapse (B), cumulative incidence of NRM (C), and cumulative incidence of acute GVHD (D).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal